Recent Advances in Combined Modality Therapy for Solid TumorsCHOY, Hak.Seminars in oncology. 2003, Vol 30, Num 4, issn 0093-7754, 124 p., SUP9Serial Issue

Taxanes in combined modality therapy for solid tumorsCHOY, Hak.Critical reviews in oncology/hematology. 2001, Vol 37, Num 3, pp 237-247, issn 1040-8428Article

Chemotherapy and irradiation interactionCHOY, Hak; KIM, Dong W.Seminars in oncology. 2003, Vol 30, Num 4, pp 3-10, issn 0093-7754, 8 p., SUP9Article

Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance?CHOY, Hak; MILAS, Luka.Journal of the National Cancer Institute. 2003, Vol 95, Num 19, pp 1440-1452, issn 0027-8874, 13 p.Article

The role of concurrent chemotherapy and radiation in the management of patients with squamous cell carcinomas of the head and neckSUNTHARALINGAM, Mohan.Seminars in oncology. 2003, Vol 30, Num 4, pp 37-45, issn 0093-7754, 9 p., SUP9Article

Cetuximab in combination therapy: from bench to clinicGERBER, David E; CHOY, Hak.Cancer metastasis reviews. 2010, Vol 29, Num 1, pp 171-180, issn 0167-7659, 10 p.Article

Combined modality therapy for esophageal cancerMINSKY, Bruce D.Seminars in oncology. 2003, Vol 30, Num 4, pp 46-55, issn 0093-7754, 10 p., SUP9Article

Combined treatment for limited small cell lung cancerKOMAKI, Ritsuko.Seminars in oncology. 2003, Vol 30, Num 4, pp 56-70, issn 0093-7754, 15 p., SUP9Article

Combined modality therapy in the treatment of gynecologic malignanciesENGLEMAN, Mark A; SMALL, William JR.Seminars in oncology. 2003, Vol 30, Num 4, pp 80-94, issn 0093-7754, 15 p., SUP9Article

Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue : The development of new cytotoxic agents in clinical oncologyCHOY, Hak; PARK, Clinton; MIN YAO et al.Clinical cancer research. 2008, Vol 14, Num 6, pp 1633-1638, issn 1078-0432, 6 p.Article

The rationale and potential of combining novel biologic therapies with radiotherapy: Focus on non-small cell lung cancerHERBST, Roy S; O'REILLY, Michael S.Seminars in oncology. 2003, Vol 30, Num 4, pp 113-123, issn 0093-7754, 11 p., SUP9Article

Combined modality management of breast cancer: Development of predictive markers through proteomicsCHAKRAVARTHY, Bapsi; PIETENPOL, Jennifer A.Seminars in oncology. 2003, Vol 30, Num 4, pp 23-36, issn 0093-7754, 14 p., SUP9Article

Standards of care for anemia management in oncology: Focus on lung carcinomaLANGER, Corey J; CHOY, Hak; GLASPY, John A et al.Cancer. 2003, Vol 95, Num 3, pp 613-623, issn 0008-543XArticle

Combined modality therapy for pancreatic cancerTSAI, James Y; IANNITTI, David A; SAFRAN, Howard et al.Seminars in oncology. 2003, Vol 30, Num 4, pp 71-79, issn 0093-7754, 9 p., SUP9Article

Combined modality treatment for prostate cancer: Role of chemotherapySANDIER, Howard M; NARAYAN, Samir; SMITH, David C et al.Seminars in oncology. 2003, Vol 30, Num 4, pp 95-100, issn 0093-7754, 6 p., SUP9Article

The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancerCHOY, Hak; MACRAE, Rob.Seminars in oncology. 2001, Vol 28, Num 4, pp 17-22, issn 0093-7754, SUP14Article

Radiation therapy for non-small cell lung cancer (NSCLC)CHOY, Hak; CHAKRAVARTHY, Anuradha; KIM, Jae-Sung et al.Cancer treatment and research. 2001, Vol 105, pp 121-148, issn 0927-3042Article

Adjuvant and neoadjuvant treatments for NSCLCVOKES, Everett E; CHOY, Hak; GANDARA, David et al.Lung cancer. 2002, Vol 38, pp S29-S35, issn 0169-5002, SUP4Article

Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapyAMORINO, George P; MOHR, Peter J; HERCULES, Sherri K et al.Cancer chemotherapy and pharmacology. 2000, Vol 46, Num 5, pp 423-426, issn 0344-5704Article

Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancerROBERTS, John R; EUSTIS, Chad; DEVORE, Russell et al.The Annals of thoracic surgery. 2001, Vol 72, Num 3, pp 885-888, issn 0003-4975Conference Paper

Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancerDONG WOOK KIM; SHYR, Yu; SHAKTOUR, Bashar et al.Lung cancer. 2005, Vol 50, Num 2, pp 235-245, issn 0169-5002, 11 p.Article

COX-2 inhibitor as a radiation enhancer: New strategies for the treatment of lung cancerSAHA, Debabrata; PYO, Hongryull; CHOY, Hak et al.American journal of clinical oncology. 2003, Vol 26, Num 4, pp 70-74, issn 0277-3732, 5 p., SUP2Conference Paper

Combined modality therapy for rectal and colon cancerCHAWLA, Ashish K; KACHNIC, Lisa A; CLARK, Jeffrey W et al.Seminars in oncology. 2003, Vol 30, Num 4, pp 101-112, issn 0093-7754, 12 p., SUP9Article

The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1β-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cellsMUKHOPADHYAY, Partha; AKTAR ALI, M; NANDI, Animesh et al.Cancer research (Baltimore). 2006, Vol 66, Num 3, pp 1758-1766, issn 0008-5472, 9 p.Article

Combined modality treatment for central nervous system malignanciesROBINS, H. Ian; PETERSON, Christopher G; MEHTA, Minesh P et al.Seminars in oncology. 2003, Vol 30, Num 4, pp 11-22, issn 0093-7754, 12 p., SUP9Article